Placenta-derived adherent cell exosomes and uses thereof
Provided herein are compositions of placenta-derived adherent cell exosomes and methods of making and using the same. In one aspect, provided herein are compositions comprising exosomes produced by and/or derived from placental cells, e.g., placenta-derived adherent cells. In certain embodiments, the exosomes provided herein are produced by placenta-derived adherent cells that have been cultured in vitro for, e.g., 1, 2, 3, 4, 5, 6 or more passages.
1. A composition comprising exosomes derived from CD10 + , CD200 + , CD105 + , CD34 − human placenta derived adherent cells, wherein said exosomes are CD9 + , CD10 + , CD13 + , CD29 + , CD44 + , CD49b + , CD49c + , CD55 + , CD59 + , CD63 + , CD73 + , CD81 + , CD82 + , CD90 + , CD98 + , CD105 + , CD141 + , CD142 + , CD151 + , CD164 + , CD295 + , or CD200 + .
2. The composition of claim 1 , wherein said exosomes are CD9 + , CD10 + , CD13 + , CD29 + , CD44 + , CD49b + , CD49c + , CD55 + , CD59 + , CD63 + , CD73 + , CD81 + , CD82 + , CD90 + , CD98 + , CD105 + , CD141 + , CD142 + , CD151 + , CD164 + , CD295 + , and CD200 + .
3. The composition of claim 1 , wherein said exosomes are additionally CD3−, CD1lb−, CD14−, CD19−, CD33−, CD192−, HLA-A−, HLA-B−, HLA-C−, HLA-DR−, CD11c− or CD34−.
4. The composition of any of claim 1 , wherein said exosomes are additionally CD3−, CD11b−, CD14−, CD19−, CD33−, CD192−, HLA-A−, HLA-B−, HLA-C−, HLA-DR−, CD11c and CD34−.
5. The composition of claim 1 , wherein said exosomes comprise non-coding RNA molecules.
6. The composition of claim 5 , wherein said RNA molecules are microRNAs.
7. The composition of claim 6 , wherein said microRNAs are miR-218-Sp, miR-133b, miR-422a, miR-564, miR-16-Sp, let-7a, miR-92, miR-142-3p, miR-451, miR-124-Sp, miR-223-3p, miR-630, miR-296-Sp, let-7b-3p or let-7d-3p.
8. The composition of any of claim 1 , wherein said exosomes comprise at least one marker molecule at a level at least two-fold higher than exosomes derived from mesenchymal stem cells.
9. The composition of claim 1 , wherein said placenta-derived adherent cells have been passaged more than 3 times.
10. The composition of any of claim 1 , wherein said placenta derived adherent cells have been maintained in culture for greater than 24 hours.
11. The composition of claim 1 , wherein at least 90% of said placenta-derived adherent cells are non-maternal in origin.
12. The composition of claim 1 , wherein at least 99% of said placenta-derived adherent cells are non-maternal in origin.
13. The composition of any of claim 1 that is in a form suitable for intravenous administration.
14. A composition comprising exosomes derived from CD10 + , CD200 + , CD105 + , CD34 − human placenta-derived adherent cells, wherein said exosomes are CD10 + and CD55 + .